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The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin
and saxagliptin do not impair innate and adaptive immune
responses
Inhibitors of dipeptidylpeptidase IV (DPP-IV) represent a novel class of frequently used anti-diabetic drugs. In addition to its function in metabolic
regulation, DPP-IV also plays a role in the immune system. Whether the DPP-IV inhibitors sitagliptin, vildagliptin or saxagliptin impair immune
responses is, however, currently unknown. Here, we investigated the effect of these agents on both innate and adaptive immunity. We found
that the DPP-IV inhibitors did not affect the innate immune response induced by Toll-like receptor (TLR) ligands, as cytokine secretion and
induction of co-stimulatory molecules by human blood mononuclear cells was not impaired. Furthermore, proliferation of T cells and suppressive
function of regulatory T cells was preserved. Mice treated with vildagliptin showed normal cytokine production, immune cell activation and
lymphocyte trafﬁcking upon TLR activation. Thus, crucial immunological parameters remain unaffected upon treatment with DPP-IV inhibitors, a
fact that is reassuring with respect to safety of these drugs.
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Introduction
The dipeptidylpeptidase-IV (DPP-IV) inhibitors sitagliptin,
vildagliptin and saxagliptin are novel drugs for the treatment
of type 2 diabetes with several advantages, as oral admin-
istration, a neutral effect on body weight and a low risk of
hypoglycaemia [1]. DPP-IV inhibitors prevent the inactivation
of glucagon-like peptide 1 and thus act against hyperglycaemia
[2]. Several reports suggest that DPP-IV also plays a role in
the immune system. DPP-IV is expressed by immune cells, in
particular by T and B lymphocytes [3,4]. DPP-IV-expressing
T cells proliferate more strongly in response to antigen-
dependent stimulation than DPP-IV-negative T cells [5] and
interaction of DPP-IV with adenosine receptors on dendritic
cells can trigger a stronger release of IFN-γ [6]. Soluble
DPP-IV enhances T cell proliferation via up-regulation of
CD86 and interaction with caveolin-1 [7]. Furthermore, the
enzymatic function of DPP-IV is immunologically relevant as
it inactivates chemokines by cleavage [8]. Thus, as DPP-IV is
involved in the regulation of the immune system it is essential
to investigate potential immunological effects of the novel
DPP-IV-inhibiting anti-diabetes drugs.
Methods
Peripheral blood mononuclear cells (PBMC) were obtained
from healthy volunteers who had given informed consent.
Correspondence to: Dr. med. David Anz, Section Gastroenterology, Department of
Medicine IV, Klinikum der Universita¨t Mu¨nchen, Ziemssenstrasse 1, 80336 Munich,
Germany.
E-mail: david.anz@med.uni-muenchen.de
Animal studies were approved by the local regulatory
agency. For in vitro use tablets were pestled and a 150mM
solution of the active component was prepared. Enzymatic
activity of DPP-IV was determined by measuring the light
absorbance of the synthetic DPP-IV substrate Z-Gly-Pro-
4-nitroanilide (Sigma-Aldrich, Munich, Germany). For ﬂow
cytometry cells were stained with the respective antibodies and
analysed by an FACSCanto II (BD Biosciences, Heidelberg,
Germany). Cytokine concentrations were determined using
enzyme-linked immunosorbent assay (ELISA) Kits (BD
Biosciences). T cell proliferation was measured by BrdU
incorporation with a chemoluminescence assay (Roche
Diagnostics, Mannheim, Germany) or by ﬂow cytometry.
CD4+CD25neg and CD4+CD25+ cells were gained by
magnetic cell sorting (Miltenyi Biotec, Bergisch Gladbach,
Germany). For lymphocyte isolation organs were disrupted,
digested using Collagenase and DNAse (Sigma-Aldrich) and
passed through a cell strainer. In vitro assays were done in
triplicates and repeated threefold, in vivo experiments were
done twice, all with similar results. Data followed Gaussian
distribution and were analysed as appropriate by unpaired
Student’s t-test or by anova test.
Results
We ﬁrst examined the production of inﬂammatory cytokines
upon Toll-like receptor (TLR) stimulation and DPP-IV
inhibition. DPP-IV inhibitors were solubilized from the tablet
(see Methods) and efﬁcient DPP-IV inhibition was conﬁrmed
both in vitro and in vivo (Figure 1A). The 105-fold dilution of
the inhibitor corresponds to the situation in patients, where
peak plasma levels of 1 μM are usual. First, human PBMC
1
Published in 'LDEHWHV2EHVLW\DQG0HWDEROLVP±
which should be cited to refer to this work.
ht
tp
://
do
c.
re
ro
.c
h
AD
PP
-IV
 a
ct
iv
ity
 (p
mo
l/s
)
Vildagliptin
0
0.5
1.0
1.5
2.0
2.5
Sitagliptin
Un
tre
ate
d
Vil
da
glip
tin
0
2
4
6
D
PP
-IV
 a
ct
iv
ity
 (p
mo
l/s
)
Ø
10-8 10-1
Saxagliptin
3.0
0
20
40
60
80 n.s.
M
H
C-
II 
(%
 po
sit
ive
 ce
lls
)
0
2000
4000
6000
CD
86
 E
xp
re
ss
io
n 
(M
FI)
n.s.
0
0.5
1.0
1.5
2.0
0
0.5
1.0
1.5
2.0
Ø
Ø
10-8 10-5
10-8 10-5
10-7 10-4
10-7 10-4
10-7 10-4
10-7 10-4
 
TL
R-
stim
 
TL
R-
stim
 
TL
R-
stim
 
TL
R-
stim
Ø
Ø
 
TL
R-
stim
 
TL
R-
stim
Ø
Ø
Cy
to
kin
e 
le
ve
l
(fo
ld 
ch
an
ge
 to
 
TL
R
-s
tim
 a
lo
ne
)
Ac
tiv
at
io
n 
m
ar
ke
rs
(fo
ld 
ch
an
ge
 
to
 T
LR
-s
tim
 a
lo
ne
)
B
C
n.s.
n.s.
n.s.
n.s.
**
*
n.s.
D
n.s.
IL-6
IL-10
IL-12
IP-10
IFN-γ
CD80
CD86
MHC-II
Sitagliptin Vildagliptin Saxagliptin
Sitagliptin Vildagliptin Saxagliptin
*
CpG + Vildaglitpin
CpG
Untreated
Figure 1. Impact of dipeptidylpeptidase-IV (DPP-IV) inhibitors on cytokines and activation markers. (A) Peripheral blood mononuclear cells (PBMC)
were treated with the indicated dilutions of a 150 mM stock of the inhibitor and DPP-IV activity was measured using the Gly-Pro-pNA assay (left).
DPP-IV activity on splenocytes was measured ex vivo after oral treatment of mice (n= 4) with 15 μg of vildagliptin every 12 h over 2 days (right). (B and
C) Human PBMC were treated with increasing concentrations of the DPP-IV inhibitor and stimulated with 1 μg/ml R848 (or 0.2 μg/ml CL097 for CD86)
for 24 h (TLR-stim), then cytokine levels (pg/ml) in the supernatants and expression of activation markers [mean ﬂuorescence intensity (MFI)] were
determined. Values are normalized to TLR stimulation alone. (D) Mice (n= 5 per group) received vildagliptin as in (A) and 100 μg of CpG (s.c.). After
24 h expression of CD86 and MHC-II on splenocytes was determined. Error bars indicate s.e.m. Signiﬁcance was calculated in comparison to untreated
(A) or only TLR-stimulated (B–D) samples (*p< 0.05, n.s.= not signiﬁcant).
were treated with the DPP-IV inhibitors and stimulated with
the TLR7 ligand R848. Levels of IL-6, IL-10, IL-12, IP-10 and
IFN-γ were not signiﬁcantly altered in the presence of the
DPP-IV inhibitors. As an exception, vildagliptin inhibited IP-
10 and IFN-γ secretion (Figure 1B), a ﬁnding that may be
reﬂected by a less speciﬁc inhibition of DDP-IV by vildagliptin
[9]. None of the DPP-IV inhibitors impaired the TLR-induced
up-regulation of the co-stimulatory molecules CD80, CD86
and MHC-II (Figure 1C). This was conﬁrmed in vivo in mice
treated with vildagliptin and the TLR9 ligand CpG (Figure 1D).
To investigate effects of DPP-IV inhibitors on T cell
activation, CD69 expression and proliferation of human T
cells was analysed. TLR7 stimulation increased CD69 levels
on T cells irrespective of DPP-IV inhibition (Figure 2A).
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Figure 2. Impact of dipeptidylpeptidase-IV (DPP-IV) inhibitors on T cell function. (A) Human peripheral bloodmononuclear cells (PBMC)were treated
with indicated dilutions of the DPP-IV inhibitor and 0.2 μg/ml of the TLR7 agonist CL097 for 24 h and expression of CD69 on CD3+ cells was determined
[mean ﬂuorescence intensity (MFI)]. (B) Human PBMC from individuals vaccinated against Tetanus were incubated with Tetanus toxoid (0.5 μg/ml) for
17 h and treated with sitagliptin. Proliferation and IFN-γ secretion was measured on day 7 by detection of BrdU and enzyme-linked immunosorbent
assay (ELISA), respectively [relative light units (RLU)]. (C and D): CD4+CD25neg cells (7.5 × 104/well) were incubated with anti-CD3 or CD4+CD25+
cells (4 × 104/well) and vildagliptin. Proliferation (BrdU incorporation, MFI) into CD4+FoxP3neg cells was determined by ﬂow cytometry. (E and F)
Mice (n= 5 per group) were treated with vildagliptin and CpG as in Figure 1. (E) 24 h later CD62L expression on T cells was determined. (F) 19 h later
CFSE+ splenocytes (2 × 103/mouse) were adoptively transferred. 6 h later lymphocytes were prepared from the indicated organs and the proportion of
CD3+ cells within the transferred CFSE+ cells was determined. Error bars indicate s.e.m. of n= 3 (A–D) or n= 5 (E and F), signiﬁcance was calculated
in comparison to the conditions without DPP-IV inhibitor (n.s. = not signiﬁcant).
Furthermore, proliferation and IFN-γ secretion of T cells
remained unimpaired upon both antigen-speciﬁc (Tetanus
toxoid) or unspeciﬁc (anti-CD3) stimulation (Figure 2B and
C). Further, regulatory T cells suppressed the proliferation of
effector T cells irrespective of DPP-IV inhibition (Figure 2D).
In addition, mice treated with CpG and vildagliptin showed
no difference in T cell activation, reﬂected by an unimpaired
suppression of the marker CD62L (Figure 2E). As chemokines
are substrates for cleavage and inactivation through DPP-IV
[8],we investigated themigrationof lymphocytes uponDPP-IV
inhibition in vivo. Mice were treated with vildagliptin and CpG,
followed by an adoptive transfer of lymphocytes. Lymphocyte
migration and distribution into several organs was, however,
not altered upon inhibition of DPP-IV (Figure 2F).
Conclusion
Stimulation of TLRs is essential for the induction of an
immune response and the clearance of pathogens by the
host [10]. An inhibition of the involved pathways could
lead to increased susceptibility to infections [11]. Although
infectious complications are not typically associated with DPP-
IV inhibitors [12] it is so far still unknown whether a higher
rate of overall infections occurs on long term. We show here
that sitagliptin, vildagliptin and saxagliptin do not inﬂuence
the development of an immune response in terms of cytokine
secretion, co-stimulation, T cell proliferation and migration.
While these ﬁndings are observed in human cells in vitro and in
mice in vivo, they are reassuring with respect to the drug safety
in patients. In conclusion, DPP-IV inhibitors do not impair
key parameters of the innate and adaptive immune response.
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